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Despite advances in understanding the pathogenesis of asthma, a number of controversies regarding the optimal clinical management of asthma remain. This review of recent literature and current controversies, chosen mainly on the basis of relevance to clinical therapy, is directed toward nonspecialists caring for asthmatic patients.
IHaMiMlfiM Recent evidence indicates asthma is mediated by airway inflammation, and maintenance therapy should include inhaled anti-inflammatory drugs. Inhaled corticosteroids are usually the first choice. However, adverse effects of long-term use are just being recognized. Optimal dosage, spacer devices, and gargling reduce these effects. Although inhaled beta agonists are essential for acute asthma management, their use in regular maintenance therapy is under reevaluation. Excessive use of beta agonists usually indicates the need for more effective anti-inflammatory therapy.
All patients should avoid allergens. A subset of asthma patients who fail to respond to treatment may benefit from immunotherapy, but there are risks. Emergency management of acute asthma should include early and frequent administration of aerosolized beta agonists and almost universal therapy with corticosteroids.
A N EXPLOSION of recent information has implicated airway inflammation in the pathogenesis of airway hyperreactivity and asthma. 1 However, even though our understanding of the pathogenesis of asthma has increased in the past decade, so has asthma morbidity and mortality. 2, 3 There are several possible reasons for these trends, but no general agreement.
In light of these trends, a number of controversies exist as to the optimal clinical management of asthma: (1) For maintenance therapy of chronic asthma, what are the optimal inhaled anti-inflammatory agents (corticosteroids, cromolyn, or nedocromil)? (2) What is the role of inhaled beta agonists in the increased mortality rate? (3) What is the role of inflammation in sudden vs gradual decompensation? (4) In status asthmaticus, what are the roles of nebulized beta agonists given continuously and intravenous aminophylline? (5) What is the role of immunotherapy? (6) What is the status of emerging, experimental therapies? This paper will explore each of these controversies point by point.
MAINTENANCE THERAPY FOR CHRONIC ASTHMA
Historically, asthma was viewed as a reversible bronchospastic disorder marked by smooth-muscle contraction. However, patients who die of status asthmaticus have extensive inflammatory changes of the airways, including mucous plugging, extensive epithelial sloughing, and inflammatory cellular infiltration of the mucosa and submucosa. 4 Studies of experimentally induced asthma and studies involving bronchoalveolar lavage and endobronchial biopsy in patients with mild, chronic asthma have contributed to the hypothesis that airway inflammation is a fundamental aspect of asthma. [5] [6] [7] This concept underlies the growing clinical and investigational interest in the use of anti-inflammatory agents such as inhaled steroids, cromolyn, and nedocromil in treating asthma.
Inhaled steroids
A number of recent bronchoalveolar lavage and biopsy studies have shown that 3 months' therapy with inhaled corticosteroids reduces inflammatory changes in patients with bronchial asthma. 8 " 10 Interestingly, a study by Lungren 11 showed that basement-membrane thickening persists even after 10 years of such therapy. Additional studies have shown that inhaled steroids reduce airway responsiveness to methacholine, histamine, or exercise. This reduction in responsiveness (as assessed by an increase in provocative concentration of histamine or methacholine) occurs over several weeks to several months, and usually ranges in the order of one or two doubling dilutions. 12, 13 Some have questioned whether these slight changes have clinical significance. 14 Recent data. Numerous recent studies have shown that inhaled steroids effectively control the symptoms of chronic asthma. Haahtela 15 conducted a prospective parallel-group trial lasting 2 years, in which 103 patients were randomly assigned to receive 600 |Xg of inhaled budesonide twice a day or 375 jLtg of inhaled terbutaline twice a day. Asthma had been diagnosed in the previous 1 year and for the most part was mild. The budesonide group enjoyed a significant reduction in symptoms, needed "rescue" with beta agonists less, and experienced an improvement in morning and evening peak expiratory flow rates. This study is limited in that the beta agonist was only given twice a day and that a spacer device was not specified for either group. Kertjens et al 16 noted that inhaled beclomethasone at 800 fXg per day improved symptoms and lung function over a 2.5-year period in patients with chronic asthma when given in addition to beta-agonist inhaled therapy. A number of studies have shown that higher doses of inhaled steroids reduce the need for maintenance oral steroids. 17 " 19 Recognition of side effects. The side effects of inhaled corticosteroids are being increasingly recognized as a potential problem. Toxicity varies with the total dose, the dosing schedule, use of a spacer device, mouth rinsing, and the sensitivity of the parameter used to assess systemic toxicity. 13, 20 The adverse effects of inhaled corticosteroids can be broadly classified as topical or systemic. The three main topical side effects are cough, oral candidiasis, and dysphonia. Slow inhalation, use of a spacer device, and gargling reduce the incidence of these side effects. 21 The systemic side effects may include suppression of the hypothalamic-pituitary-adrenal (HPA) axis, adverse effects on bone metabolism (leading to osteoporosis), slowing of growth in children and adolescents, cataracts, bruising, dermal thinning, and psychological changes. Many studies have suggested that doses of inhaled corticosteroids in excess of 800 jag/day in adults or 400 (J-g/day in children can suppress the HPA axis in a dose-related manner, although the response varies substantially among individuals. 20 HPA-axis suppression has been most commonly assessed by measuring the morning serum Cortisol level and 24-hour urinary Cortisol excretion. The clinical significance of these changes over the long duration is not known. In patients who require more than 800 |Xg, the use of a spacer device in conjunction with a metered-dose inhaler (MDI) and the use of mouthwashing may reduce suppression of the HPA axis. Twice-a-day dosing appears to have fewer side effects. Some studies suggest that, at higher doses, beclomethasone may have a somewhat greater propensity to produce adrenal suppression than budesonide does, although the relevance of this is not clear. Inhaled corticosteroids in doses as low as 400 |J,g/day have been associated with the development of osteoporosis. 22 when administered before challenge. The protective effects against nonspecific agents such as methacholine and histamine have been less established. 24 A number of studies have evaluated the effect of CS on nonspecific bronchial hyperreactivity. Studies in which CS was administered for longer than 6 weeks suggest airway reactivity decreases.
Despite initial notions that CS would be more effective in extrinsic than intrinsic asthma, most carefully designed studies do not support this concept. 23 About 60% to 79% of asthma patients show a response to CS. 23 A 3-month, double-blind, placebo-controlled clinical trial found CS effective in chronic adult asthma. 25 Studies comparing CS and theophylline in the short-term management of chronic asthma suggest that both of these agents are equally effective, with perhaps greater side effects with theophylline. 26 There are some data to show that there is an additive effect between these two agents. 23 A study by Shapiro et al 27 demonstrated that CS was as effective as triamcinolone in children. However, in a 6-month trial in adult patients, CS did not reduce the need for beclomethasone. 28 
Nedocromil sodium
Nedocromil sodium (NS) was approved in the United States in 1993 for use in MDIs. NS is structurally different from CS but has very similar pharmacologic activities and a similar mechanism of action. A number of in vitro and in vivo studies suggest that NS blocks both the early and late asthmatic response, has anti-inflammatory effects on a number of cells, and may be more potent than CS is in inhibiting bronchial C-fiber nerve endings.
A recent meta-analysis reviewed all known placebo-controlled, double-blind, randomized clinical trials of NS (a total of 4723 patients from 127 centers). 29 This included both published and unpublished material. The authors compared the effects of NS and placebo using six efficacy variables, including symptom scores, peak flows, forced expiratory volume in 1 second (FEVi), and inhaled bronchodilator use. The study found NS more effective than placebo and of most benefit to patients receiving monotherapy with bronchodilators. 30 " 32 The aggregate data suggested that NS is less potent than inhaled corticosteroids, although some inhaled corticosteroid-sparing effects were noted. A recent NS workshop concluded that NS could represent an alternative to CS, although it has no clear advantage over inhaled steroids and costs more. 33 
Chronic asthma: recommendations
Overall, inhaled anti-inflammatory agents should be part of the maintenance regimen for most patients with chronic asthma. Inhaled corticosteroids are preferred in most patients because of proven efficacy, greater potency than CS or NS, and effectiveness when administered twice a day as opposed to four times a day. 34 Also, there are more data supporting improvement of inflammation as assessed by bronchoalveolar lavage and endobronchial biopsy in patients treated with inhaled corticosteroids. 35 In patients at risk of toxicity from inhaled corticosteroids (ie, children or patients requiring high doses of inhaled corticosteroids), CS or NS are rational alternatives. Also, in patients who continue to have symptoms despite very high doses of inhaled corticosteroids, the addition of NS seems reasonable. 35 " 37 Additional studies directly comparing inhaled corticosteroids and NS for newly diagnosed bronchial asthma are required.
DO BETA AGONISTS INCREASE MORTALITY?
Much controversy surrounds the possible role of beta agonists in the increasing asthma mortality rate. 14 ' 38 ' 39 According to one hypothesis, excessive or regular use of beta-adrenergic bronchodilators can actually worsen asthma, perhaps contributing to morbidity and mortality. Several studies from New Zealand suggested that inhaled beta agonists increase the risk of death in severe asthma. 40, 41 In patients with mild, stable asthma, Sears et al 42 evaluated the effects of regular vs "on-demand" inhaled fenoterol therapy in a 24-week, placebo-controlled, crossover study. In the 57 patients who did better with one of the two regimens, only 30% had better asthma control when taking fenoterol on a regular schedule, whereas 70% did better when they used it only as needed. This study has been widely criticized, 39 for several reasons: (1) The patients had mild asthma, requiring only 2.9 doses per day via an MDI, and were excluded if they required more than eight doses per day. (2) The beta agonist employed, fenoterol, produces significantly greater beta-adrenergic stimulation and has an intrinsically shorter duration of action than beta agonists used in the United States. (3) Subjects were not permitted to use any other bronchodilators. (4) The data presented in the study were qualitative, with no indication of the magnitude of the differences or means of assessing possible clinical significance.
In a second welbpublicized, matched, case-control study, Spitzer et al 43 used a health insurance data base from Saskatchewan, Canada to identify a cohort of 12 301 patients for whom asthma medications had been prescribed. The investigators matched 129 case patients who had fatal or near-fatal asthma with 655 controls. The use of a beta agonist via an MDI was associated with an increased risk of death from asthma, an odds ratio of 5.4 per canister of fenoterol and 2.4 per canister of albuterol.
The primary limitation of this study, and indeed, case-control studies in general, is that the two groups may have differed in the severity of the underlying disease. Because sicker patients were both more likely to die and more likely to have received an inhaled beta agonist, it is difficult to judge the independent effect of the drug. Indeed, the subjects who died used all antiasthma medications more than the controls did. However, in a subsequent report, the same authors adjusted for disease severity and still found a significant correlation between beta-agonist use and asthma mortality. 44 A recent meta-analysis evaluated the association between beta-agonist use and death due to asthma in six case-control studies. Statistical integration revealed a significant, although extremely weak, relation between beta-agonist use and asthma death, but only for beta agonists given with a nebulizer, not with an MDI. 45 
Beta agonist use: recommendations
Overall, the exact contribution of beta agonists to the recent mortality trend remains unknown. There is sufficient concern regarding fenoterol to justify avoiding its use. Also, if patients require an increasing number of puffs of other beta-agonist aerosols, this usually indicates the need for more effective anti-inflammatory therapy. Beta-agonist aerosols remain a critical part of the regimen for acute emergency management of bronchial asthma. However, whether they should be avoided in longterm maintenance therapy remains unknown. The National Asthma Education Program (NAEP) guidelines recommend that inhaled beta agonists be used as needed. 1 If a patient needs more than three or four puffs a day of a beta agonist, additional therapy should be considered.
WHAT IS THE ROLE OF INFLAMMATION IN SUDDEN VS GRADUAL DECOMPENSATION?
Although inflammation is now understood to play a fundamental role in asthma, the relationship between airway inflammation and bronchial hyperreactivity remains unclear. 46, 47 Also, whether inflammation is as important in the subset of patients who present with sudden, "hyperacute" decompensation remains poorly understood.
Numerous retrospective studies have examined the circumstances of asthma-related deaths. 48 " 50 In addition, several case-control studies compared patients who died of asthma with matched survivors. 51, 52 These and other studies suggest that asthma deaths can be classified as either type 1 (slow-onset, late-arrival) or type 2 (sudden-onset). 53 The consensus from these studies is that several risk factors contribute to type-1 fatal asthma, including previous serious asthma requiring emergency-room visits or mechanical ventilation. Socioeconomic status, psychological features, race, and culture may interfere with compliance and access to medical care. Other factors include failure to perform pulmonary function testing to objectively assess asthma severity. Inadequate treatment with either inhaled or systemic anti-inflammatory agents is also frequently described. Therefore, underestimation of asthma severity and undertreatment of asthma are important contributing factors in type-1 asthma-related fatalities. 54 A number of recent studies have highlighted that some patients die suddenly and unexpectedly of acute (type 2) asthma. Wasserfallen 55 analyzed the interval between onset of symptoms and endotracheal intubation in 34 patients who required intubation and mechanical ventilation because of severe asthma. Three patterns of decompensation were noted: rapid (less than 3 hours), gradual (9.2 ± 7.7 days), and acute after unstable asthma (4.2 ± 3.6 days). The rapid, sudden, asphyxie type was more frequent in young men and was associated with extreme hypercapnia and a higher incidence of respiratory arrest, but these patients recovered faster and did not need mechanical ventilation as long. The authors suggested that bronchospasm was a primary mechanism in this group.
Kallenbach 56 studied 81 patients who had acute asthma that required mechanical ventilation. Patients with hyperacute attacks in which less than 3 hours elapsed from onset of attack to mechanical
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CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 62 • NUMBER 5 ventilation had a significantly higher rate of near-fatality. They also had a more rapid response to bronchodilators and a shorter duration of mechanical ventilation. Sur et al 57 studied the histologic differences in the airways of three patients who died of sudden-onset (type 2) asthma and four patients who died of the more common, slow-onset (type 1) asthma. In the sudden-onset group, neutrophils exceeded eosinophils in the airway submucosa. The authors concluded that sudden-onset fatal asthma is immunohistologically distinct from slow-onset fatal asthma.
Status asthmaticus: recommendations
Therefore, a relatively small subset of patients appears to have status asthmaticus that has a predominately hyperacute, bronchospastic component. 58, 59 Whether the fundamental mechanism in this subset is bronchospasm or a yet-unknown inflammatory process remains to be established. Certainly, any patient with status asthmaticus should be maximally treated with an inhaled beta agonist and a systemic anti-inflammatory drug. 60 
EMERGENCY MANAGEMENT
For patients who have acute, severe asthma, there is debate about the best way to administer beta agonists and whether the use of aminophylline is appropriate.
Nebulized beta agonists: continuous or intermittent?
Even though in many studies beta agonists produced comparable bronchodilation whether given via an MDI or a nebulizer, 61 " 63 the NAEP expert panel recommends wet nebulization for emergency management of asthma. 1 Nebulized therapy continues to be widely used, for a number of reasons. Acutely tachypneic patients are felt not to be able to optimally use MDIs, even with a "spacer" device. Further, patients usually use an MDI at home, and an acute episode requiring emergency care typically represents a failure of home therapy for which patients expect a different form of therapy. Finally, there is a continued, widespread belief that nebulized therapy is more effective than MDI therapy in treating acute exacerbation of airway obstruction.
Much evidence suggests that patients with acute, severe airflow obstruction need higher dosages of aerosolized beta agonists than do those with less severe, stable airway obstruction. In many hospitals, standard therapy for acutely ill patients involves giving a beta agonist at 20-to 30-minute intervals. A number of studies have suggested that beta agonists may be effective and safe when given continuously by a variety of nebulization devices for up to 72 or 96 hours in children. 64, 65 Two studies have extended these findings to adults. 66, 67 Colacone and associates 66 randomly assigned 42 patients with acute, severe asthma to receive either 5 mg of albuterol by intermittent bolus nebulization immediately and 60 minutes later or 0.2 mg/mL continuously by a calibrated nebulizer with an output of 25 mL/hour. Each patient received 10 mg of albuterol over 2 hours. The authors found both regimens equally effective and well tolerated. Interestingly, the heart rate was significantly higher at 30 and 90 minutes in the bolus nebulization group than in the continuous nebulization group.
Olshaker and associates 67 performed an open-label, prospective study in 76 adults who had acute asthma exacerbations. The patients were given three continuous nebulizer treatments over 45 minutes in the emergency room; each dose contained 2.5 mg of albuterol and 3 mL of normal saline. All patients showed objective and subjective improvement, including an average improvement in peak flow of 150% over baseline. This therapy was well tolerated and produced no significant tachyrhythmia, even though the patients had underlying hypertension and coronary artery disease.
In a study by Lin and colleagues, 68 seven adults (mean age 30.9 years) with asthma were given nebulized albuterol at 0.4 mg/kg/hour continuously for 4 hours. Patients with coronary artery disease were excluded. The FEVi improved significantly, and the mean heart rate increased by 16.3%. One patient withdrew because of supraventricular tachycardia. Six of the seven patients had serum albuterol levels greater than 25 ng/mL at the end of treatment. The authors concluded that continuous use of high-dose, nebulized albuterol can result in markedly high serum albuterol levels and potential cardiac stimulation in some patients.
Patients with acute airflow obstruction refractory to intermittent, frequent, aerosolized beta-agonist therapy may be candidates for continuous therapy with a nebulized bronchodilator while awaiting the effects of anti-inflammatory therapy. 69 Recommended regimens are albuterol 2.5 to 15 mg/hour or terbutaline 2 to 8 mg/hour. A variety of delivery methods for continuous nebulization have been described. Patients should receive continuous treatment until they have improved enough to tolerate intermittent aerosol treatment every 4 hours. Extensive experience in children and the two reports in adults suggest that this approach is safe, although further studies in adults with underlying coronary artery disease are required.
Aminophylline
The role of aminophylline in the treatment of acute, severe asthma remains controversial. The NAEP expert panel on the diagnosis and management of asthma did not recommended using aminophylline routinely in the emergency treatment of asthma. However, both the NAEP expert panel and the British Thoracic Society did recommend the routine use of oral or intravenous theophylline in patients admitted to the hospital for an acute exacerbation of asthma. 1 ' 70 Early studies in the emergency room suggested that the addition of aminophylline to maximal therapy with inhaled beta agonists had little effect on pulmonary function during 3 hours of observation. 71 " 73 A recent meta-analysis of 13 controlled trials found no overall benefit of using aminophylline: three studies favored aminophylline therapy, three favored a control regimen consisting of albuterol, epinephrine, or other sympathomimetic bronchodilators, and seven showed no difference between the two. 74 More recently, a number of studies have evaluated the role of aminophylline in the treatment of acute exacerbation of asthma when used in addition to inhaled beta agonists and intravenous corticosteroids both in the emergency room and in the hospital for both adults and children. 75 " 80 In a prospective study of 133 adult patients maximally treated with intravenous corticosteroids and inhaled beta agonists, patients who received aminophylline had a threefold lower hospital admission rate (6%) than did placebo recipients (21%). 76 This was surprising, because aminophylline produced no effect on pulmonary function as measured by spirometry. The admission decision was made by house staff not involved in the study, who used preexisting guidelines for admission.
Huang, 78 in a placebo-controlled randomized trial of aminophylline infusion in addition to inhaled albuterol and intravenous methylprednisolone, found the improvement in FEVi at 3 hours was greater in the aminophylline group (29% ±23% compared with 10% ± 10%) and that the aminophylline-treated patients required fewer doses of nebulized albuterol. A concern with this study is whether the patients received maximal dosages of the inhaled beta agonist. Also, it is unclear how the decision to administer "as-needed" albuterol therapy was made, even though this was one of the end points of the study. In contrast, two recent studies in children maximally treated with nebulized albuterol and intravenous corticosteroids did not find the addition of intravenous aminophylline beneficial. 79, 80 Emergency management: recommendations In summary, emergency management of acute asthma should include early and frequent administration of aerosolized beta agonists and almost universal therapy with systemic corticosteroids. Frequent reassessment for response with a peak flow meter should be performed. Which subset of patients may benefit from continuous aerosolized beta agonists remains poorly understood. Finally, according to NAEP guidelines, aminophylline should be administered only to patients with acute asthma who require hospital admission. 1 
WHAT IS THE ROLE OF IMMUNOTHERAPY IN ASTHMA?
Immunotherapy (IT) has been used to treat allergic disorders since the early 1900s. Although IT has been accepted in the treatment of allergic rhinoconjunctivitis, its use in asthma has been controversial, owing to a number of factors. The pathogenesis of asthma and the role of precipitating triggers, allergic and nonallergic, remain poorly defined. IT is not standardized, having inconsistencies in extract potency and in preparation, methods of administration, and total duration of therapy.
Approximately 100 controlled studies of IT for the treatment of asthma have been performed, 81 some of which were double-blinded. With regard to specific allergens, there is evidence to support the use of dust mite extract, 82, 83 pollen extract, 84 " 86 and cat and dog dander extract. 87, 88 Animal dander IT is recommended for patients who cannot avoid animals owing to their occupation, such as veterinarians and laboratory technicians. However, this is not a uniform opinion among allergists. Few studies of mold IT have been done, but efficacy has been demonstrated for Chdosporium 89 and Alternaria. 90 These studies were performed in Europe, where stand-ardized mold extract is available. At this time, indications for mold IT are few, as mold extract preparation, purification, and standardization in the United States are unresolved issues. 91 While not all studies of IT have shown benefit, many have shown reduction of asthma symptoms. [82] [83] [84] [85] 89 Some studies have even indicated decreases in bronchial hyperresponsiveness after long-term IT. 82, 86 Because studies have used different definitions of asthma, different IT regimens, and different outcomes, assessing the efficacy of allergen IT in the treatment of asthma has been difficult. A recent meta-analysis addressing this question included 20 randomized, double-blinded, placebo-controlled trials and demonstrated that allergen IT significantly reduced asthma symptoms, bronchial hyperresponsiveness, and medication requirements in asthmatic patients. 92 The authors concluded that allergen IT is a "useful adjunct to therapy in extrinsic ("allergic") asthma." Further studies to strengthen the role of allergen IT in the treatment of asthma should be multicenter, double-blinded, and placebo-controlled and use standardized allergen extracts. Additional factors, such as nonallergic triggers causing exacerbations and seasonal variation of allergens and of allergic asthma, also need to be addressed in these trials.
Immunotherapy: recommendations
Despite the effectiveness of IT in some studies, recommendations for the treatment of allergic asthma begin with allergen avoidance. 1 This is advised for all asthma patients, regardless of the severity of disease. Second-line treatment is judicious use of asthma medications. 1 With the advent of potent inhaled corticosteroids and effective inhaled beta agonists, many patients can be well controlled with these medications. CS and NS are also effective in allergic asthma.
IT should be considered when: (1) triggers of clinical symptoms clearly correlate with specific allergens; (2) avoidance measures and medications fail to adequately control symptoms; (3) the patient is unable to tolerate asthma medications because of toxicity or adverse effects; (4) allergen exposure is occupationally related and avoidance is unacceptable; (5) seasonal rhinitis occurs concomitantly with seasonal asthma; and (6) the risks and benefits of IT have been thoroughly discussed with the patient. Therefore, IT is not indicated for all asthma patients with positive skin tests, and for many patients, is not even necessary. Moreover, IT can be life-threatening; asthma patients may have more severe reactions to allergy shots than patients receiving IT for allergic rhinitis. 93 The risks must be discussed with the patient and weighed against the benefits.
Therefore, at present, IT in the treatment of allergic asthma is reserved for patients who are unable to achieve substantial relief of symptoms with avoidance measures and pharmacotherapy. It is hoped that future studies with standardized IT will demonstrate more clearly its efficacy. Improved preparations, such as polymerized allergens or allergoids, may also determine the role of IT in asthma therapy, as these may be more effective and safer. While current evidence supports the use of IT in allergic asthma patients, its exact role continues to evolve.
EMERGING THERAPIES
A minority of asthma patients-perhaps 5% to 20%-continue to have troublesome symptoms with frequent exacerbations that necessitate hospitalization despite maximal conventional therapy. The reversible factors that contribute to "steroid-dependent" asthma include noncompliance, poor selfmanagement strategies, inadequate control of allergen burden at home, inadequate inhaler technique, and suboptimal pharmacotherapy. The placebo arms of a number of studies have clearly shown that a compulsive traditional management plan, with frequent follow-up (perhaps in an asthma center), can reduce the need for oral steroids by 16% to 40% in "steroid-dependent" asthma. Numerous studies have demonstrated the efficacy of alternative antiinflammatory therapies that provide a steroid-sparing effect in asthma. Methotrexate, gold salts, troleandomycin, cyclosporine, leukotriene antagonists, colchicine, chloroquine, gamma globulin, and dapsone are some of the agents that have been investigated.
Glucocorticoid'resistant asthma
Carmichael 94 described 58 patients with chronic asthma in whom the FEVi increased less than 15% after a 7-day course of at least 20 mg of prednisolone daily. Dykewicz 95 studied the natural history of asthma in 40 randomly selected adults with asthma refractory to inhaled beclomethasone and beta agonists, and dependent on long-term prednisone therapy (mean duration 6.2 ± 5 years). Over 3 to 5 years, 24 patients (60%) had unchanged prednisone requirements, 13 patients (32.5%) improved and required less prednisone, and three patients (7.5%) deteriorated and required more prednisone. Unfortunately, this study did not report the maintenance dose of beclomethasone.
Corrigan et al 96 evaluated the possible mechanism of chronic asthma in patients with clinical glucocorticoid resistance (less than a 30% increase in FEVi after 2 weeks of daily prednisone treatment, 20 mg for the first week and 40 mg for the second week). Glucocorticoid pharmacokinetics, receptor characteristics, and inhibition of peripheral blood T-cell proliferation by prednisone were assayed. Overall, the investigators noted a relative insensitivity of T lymphocytes to prednisone in patients with clinical glucocorticoid resistance compared with matched glucocorticoid-sensitive patients. They noted that resistance does not reflect abnormal glucocorticoid clearance. Additional studies by this group suggested that activated T lymphocytes may be the target, and perhaps an anti-T-lymphocyte drug such as cyclosporine may be particularly useful in glucocorticoid-resistant asthma. 96 Overall, the clinical relevance of glucocorticoid resistance in patients with chronic steroid-dependent asthma remains speculative and poorly understood.
Methotrexate
Methotrexate, an inhibitor of dihydrofolate reductase, appears to inhibit neutrophil-dependent inflammation. Methotrexate has been evaluated in steroid-dependent asthma in five recent clinical trials, 97 " 102 following long experience with this drug in rheumatoid arthritis and psoriasis.
Mullarkey et al 97 conducted a placebo-controlled crossover study in 14 steroid-dependent asthma patients. The average starting prednisone dose was 26 mg/day (range 10 to 60 mg). Patients were randomly assigned to receive either placebo or methotrexate (15 mg by mouth per week) for 12 weeks, and then were switched to the alternate form of therapy. They were seen every 3 weeks in follow-up. On the average, patients needed 36.5% less prednisone when they were receiving methotrexate than when they received placebo.
The same group published a follow-up experience of 31 cushingoid asthma patients who were receiving prednisone and inhaled corticosteroids daily. Patients were treated with low-dose methotrexate for 18 to 28 months. 98 The mean prednisone dose declined, from 26.9 mg/day to 6.3 mg/day in the 25 patients who completed the study, and 15 patients stopped using prednisone regularly.
Similarly, Shiner 100 conducted a 24-week, placebo-controlled trial in 69 steroid-dependent asthma patients. The mean daily prednisolone dose was 14.2 mg/day. During 12 weeks of treatment, steroid doses were tapered by 16% in both the methotrexate and placebo groups. However, between 12 and 24 weeks, the prednisolone dose was reduced more in the methotrexate group than in the placebo group (50% vs 14%). Patients were evaluated every 4 weeks in the study. Five of the 38 patients taking methotrexate had liver function abnormalities.
Erzurum et al 101 conducted a double-blind, parallel-group study over 13 weeks in prednisone-dependent asthma (average daily dose 20 mg, range 15 to 30 mg), in which 19 patients received either methotrexate (5 mg intramuscularly every week) or placebo. This study was unique in that patients were seen weekly and there was a 1-month baseline period during which conventional therapy was maximized and attempts to reduce the baseline prednisone dose were made. Overall, both groups reduced their oral prednisone dose by about 40%. The authors concluded that methotrexate did not produce significant benefit in corticosteroid-dependent asthma.
More recently, Coffey et al 102 evaluated 11 subjects who had steroid-dependent asthma (mean prednisone dose 28 mg/day) in a 12-week placebocontrolled crossover trial. The placebo group was able to reduce their prednisone dose by about 20%, and methotrexate was not superior to placebo. In summary, based on the available studies, it is difficult to recommend therapy with methotrexate outside the setting of a clinical trial.
Gold
Both oral and parenteral gold preparations have been used in studies of steroid-dependent asthma. 103 " 106 In general, the addition of gold decreased corticosteroid requirements, improved symptoms, and perhaps improved bronchial hyperreactivity as well. However, these studies had a number of methodologic limitations. Further, overall patient tolerance was poor: the incidence of side effects, including diarrhea, skin eruptions, and proteinuria, was as high as 37%. There are no data on long-term side effects or patient compliance with gold therapy for patients with bronchial asthma.
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Troleandomycin
Another steroid-sparing approach in the treatment of chronic asthma is the use of troleandomycin (TAO), a macrolide antibiotic. A number of openlabel studies have demonstrated a reduction in corticosteroid dose when this drug was added to the regimen. 107 " 110 The principal effect of TAO is the prolongation of plasma half-life of corticosteroids through the inhibition of their elimination; in one study, the methylprednisolone half-life increased from 2.46 hours before TAO therapy to 4.63 hours 1 week after TAO therapy. 108 Published protocols highlight the importance of using methylprednisolone rather than prednisone in conjunction with TAO to have the steroid-sparing effect. 110, 111 A recent, 2-year, placebo-controlled, parallel group study was performed in 75 steroid-dependent asthma patients to compare TAO plus methylprednisolone vs methylprednisolone alone. 112 Patients in both groups achieved alternate-day steroid therapy, and the reduction in methylprednisolone dose was not significantly different between the treatment groups. However, the patients in the TAO group had significantly more steroid-related side effects as assessed by serum levels of IgG, glucose, and cholesterol, and as reflected by osteoporosis. This well-designed study strongly supports the notion that the steroid-sparing properties of TAO are a pharmacologic phenomenon that do not translate into fewer long-term steroid-related side effects. This study indicates that further trials with TAO are probably not indicated.
Cyclosporine
The immunosuppressive agent cyclosporine inhibits mediator release from mast cells and basophils and inhibits the synthesis of lymphokines, with the subsequent down-regulation of CD4 + T lymphocytes. Since recent data have implicated the T lymphocyte as playing a critical role in chronic asthma, a number of investigators have evaluated cyclosporine in steroid-dependent asthma. 113, 114 Most recently, Alexander 114 conducted a double-blind, placebocontrolled, crossover trial of cyclosporine (initial dose 5 mg/kg/day) or placebo for 12 weeks with a 2-week washout period. In 30 of 33 patients in the cyclosporine group, the peak expiratory flow rate and FEVi increased significantly and the frequency of disease exacerbations was 48% lower. Corticosteroid dosage reduction was not attempted in this study. The well-known side effects of cyclosporine include hypertension, hypertrichosis, neurological disturbances, and nephrotoxicity.
Leukotriene antagonists
The sulfidopeptide or cysteinyl leukotrienes (LTC4, LTD4, and LTE4), formerly known as the slow-reacting substance of anaphylaxis (SRS-A), are formed by the lipoxygenation of arachidonic acid by the enzyme 5-lipoxygenase. 115, 116 Much data over the past 10 years suggest that the cysteinyl leukotrienes play a role in spontaneously occurring human asthma. These compounds, released by mast cells and eosinophils, have a variety of potent effects, including bronchoconstriction, increased permeability, and enhanced airway reactivity. The cysteinyl leukotrienes can be recovered from nasal secretions, bronchoalveolar lavage fluid, and urine of patients with asthma. 117, 118 A number of recently developed pharmacologic antagonists further support the role of leukotrienes in a number of models of human asthma. Specifically, potent competitive receptor antagonists to LTD4 inhibit asthmatic responses to allergens, exercise, cold dry air, and aspirin. 119 " 121 A 5-lipoxygenase inhibitor, zileuton, was recently evaluated in the treatment of mild to moderate chronic asthma in a 4-week, placebo-controlled, parallel study. 122 A total of 139 asthma patients with an FEVi between 40% and 75%, who were not receiving other therapy, were randomized to receive zileuton 2.4 g/day or 1.6 g/day or placebo. Zileuton increased the FEVi by 14.6% within 1 hour of administration. In addition, after 4 weeks of zileuton therapy, there was a 13.4% increase in FEVi from baseline along with a reduction in symptoms and in the frequency of beta-agonist use. Cysteinyl leukotriene production, as reflected by recovery of LTE4 in the urine, decreased by 39% at the dose of 2.4 g/day. This study supports the notion that long-term inhibition of leukotriene synthesis at the 5-lipoxygenase level may produce a clinically relevant benefit. This agent was well tolerated, but long-term studies need to be performed.
UNRESOLVED ISSUES
Much new information has emerged from intensive research in asthma in the past 5 to 10 years. However, as evidenced by a recent consensus conference, 1 there are many unresolved questions regarding the fundamental factors involved in the pathogenesis of asthma, the etiology of upward trends in morbidity and mortality of asthma, and the utility of newer therapeutic agents in the long-term management of asthma. How do genetic factors, atopic status, and environmental factors (including allergen exposure, viral infections, and atmospheric pollutants) interact to produce the familiar symptoms of the airway disease? Is asthma a single disorder with a unique cause or a syndrome of multiple disorders with several etiologic mechanisms? What are the critical and rate-limiting steps in the asthma inflammatory cascade? Also, what is the natural history of the disease, the significance of airway hyperreactivity in asymptomatic individuals, the impact of long-term anti-inflammatory therapy, and the toxicity of long-term therapy? Future therapeutic strategies will in large part depend on the answers to some of these unresolved issues.
